Yvonne McGrath
Director Técnico/Científico/I+D en ITEOS THERAPEUTICS, INC. .
Fortuna: 328 600 $ al 30/04/2024
Cargos activos de Yvonne McGrath
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ITEOS THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/05/2020 | - |
Historial de carrera de Yvonne McGrath
Antiguos cargos conocidos de Yvonne McGrath.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Director/Miembro de la Junta | 01/05/2014 | 01/04/2020 |
| Director Técnico/Científico/I+D | 01/05/2014 | 01/04/2020 | |
| IMMUNOCORE HOLDINGS PLC | Corporate Officer/Principal | 01/01/2010 | 01/04/2014 |
Formación de Yvonne McGrath.
| The University of Wales | Doctorate Degree |
| Queen’S University Belfast | Undergraduate Degree |
Estadísticas
Internacional
| Reino Unido | 4 |
| Bélgica | 2 |
| Estados Unidos | 2 |
Operativa
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| IMMUNOCORE HOLDINGS PLC | Health Technology |
| ITEOS THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Complix NV
Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Health Technology |
- Bolsa de valores
- Insiders
- Yvonne McGrath
- Experiencia
